1. GPCR/G Protein
  2. GNRH Receptor


Cat. No.: HY-16168A Purity: 99.92%
Handling Instructions

Degarelix is a competitive gonadotropin-releasing hormone receptor (GnRHR) antagonist for the treatment of androgen-dependent advanced prostate cancer.

For research use only. We do not sell to patients.
Degarelix Chemical Structure

Degarelix Chemical Structure

CAS No. : 214766-78-6

Size Price Stock Quantity
10 mM * 1 mL in Water USD 539 In-stock
2 mg USD 108 In-stock
5 mg USD 180 In-stock
10 mg USD 300 In-stock
50 mg USD 1020 In-stock
100 mg USD 1920 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Degarelix is a competitive gonadotropin-releasing hormone receptor (GnRHR) antagonist for the treatment of androgen-dependent advanced prostate cancer.

In Vitro

Degarelix acts directly on the pituitary receptors for luteinizing hormone-releasing hormone (LHRH), blocking the action of endogenous LHRH. The use of degarelix eliminates the initial undesirable surge in gonadotropin and testosterone levels, which is produced by agonists of LHRH[1]. Degarelix treatment reduces cell viability in all prostate cell lines (WPE1-NA22, WPMY-1, BPH-1 cells, VCaP cells), with the exception of the PC-3 cells. The GnRH antagonist degarelix exerts a direct effect on prostate cell growth through apoptosis[2].

In Vivo

At single subcutaneous injections of 0.3 to 10 μg/kg in rats, degarelix produces a dose-dependent suppression of the pituitary-gonadal axis as revealed by the decrease in plasma luteinizing hormone (LH) and testosterone levels. Duration of LH suppression increases with the dose: in the rat, significant suppression of LH lasted 1, 2, and 7 days after a single subcutaneous injection of degarelix at 12.5, 50, or 200 μg/kg, respectively[3]. Degarelix is stable when incubated in microsomes and cryopreserved hepatocytes from animal liver tissue. In rat and dog, most of the degarelix dose is eliminated within 48 h via urine and feces in equal amounts (40–50% in each matrix), whereas in monkey the major route of excretion is fecal (50%) and renal (22%)[4].

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 0.6126 mL 3.0632 mL 6.1265 mL
5 mM 0.1225 mL 0.6126 mL 1.2253 mL
10 mM 0.0613 mL 0.3063 mL 0.6126 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay

Cells are allowed to attach for 24–48 hours (h). After that, they are treated with different concentrations of degarelix, a GnRH antagonist (0.1 to 10 μM). 10 μL of MTT labeling reagent is added to each well and the plates are incubated at 37°C for 4h. Then, 100 μL of solubilization solution is added, and the plates are incubated at 37°C, overnight, in a humidified atmosphere. The final reaction is measured at 550–600 nm. The obtained absorbance directly correlates to the number of live and metabolically active cells, providing an indication of cell viability[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Rats: To study the absorption, distribution, metabolism, and excretion, male and female rats are dosed with 30 μg [3H]degarelix free base peptide/kg (-300 μCi/kg). Feces, heparin plasma, and urine samples from groups A and B are collected up to 240 h after dosing. Bile sampling from cannulated rats (group C) as well as urine and feces are collected for up to 48 h. All samples in this study are analyzed by LC-RAD at the contract research[4].

Monkeys: Four male cynomolgus Monkeys (4.2-7.5 kg) are dosed for a disposition of radioactivity study. The animals are administered a single subcutaneous dose of 8.2 μg/kg (200 μCi/kg) [3H]degarelix. Urine and feces samples are collected quantitatively from each animal after dosing until the time of sacrifice. Blood samples are collected at the time of the sacrifice of the individual animal (6, 24, 48, and 240 h) into tubes containing EDTA as an anticoagulant[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight







C[[email protected]](C(N)=O)NC([[email protected]]1N(C([[email protected]](CCCCNC(C)C)NC([[email protected]](CC(C)C)NC([[email protected]@H](CC2=CC=C(NC(N)=O)C=C2)NC([[email protected]](CC3=CC=C(NC([[email protected]](CC(N4)=O)NC4=O)=O)C=C3)NC([[email protected]](CO)NC([[email protected]@H](CC5=CC=CN=C5)NC([[email protected]@H](CC6=CC=C(Cl)C=C6)NC([[email protected]@H](CC7=CC=C8C=CC=CC8=C7)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O

Powder -20°C 3 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: ≥ 500 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.92%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: